Denali Therapeutics Inc.
DNLI
$14.05
-$0.27-1.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -230.75% | -191.12% | -243.56% | -226.90% | 62.96% |
| Total Depreciation and Amortization | -75.77% | -93.47% | -54.13% | -54.22% | -51.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.82% | -5.60% | -36.04% | -44.96% | -50.84% |
| Change in Net Operating Assets | 103.30% | 105.84% | 104.14% | 91.65% | -1,076.91% |
| Cash from Operations | 11.45% | 2.88% | -9.23% | -29.56% | -78.39% |
| Capital Expenditure | -53.13% | -22.98% | 16.06% | 42.47% | 25.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 506.65% | -127.78% | -372.14% | -881.99% | 0.79% |
| Cash from Investing | 444.70% | -135.60% | -485.85% | -391.09% | 4.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.63% | 2,804.61% | 65.67% | 63.18% | 66.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -- | -- | -- |
| Cash from Financing | -103.82% | 2,617.76% | 57.68% | 63.03% | 66.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.99% | 152.67% | -294.68% | -148.67% | 79.68% |